Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.64
RHHBY's Cash to Debt is ranked higher than
53% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. RHHBY: 0.64 )
RHHBY' s 10-Year Cash to Debt Range
Min: 0.36   Max: 5.08
Current: 0.64

0.36
5.08
Equity to Asset 0.34
RHHBY's Equity to Asset is ranked higher than
55% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RHHBY: 0.34 )
RHHBY' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.59
Current: 0.34

0.13
0.59
F-Score: 7
Z-Score: 5.15
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 34.30
RHHBY's Operating margin (%) is ranked higher than
96% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. RHHBY: 34.30 )
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.49   Max: 35.01
Current: 34.3

4.49
35.01
Net-margin (%) 23.15
RHHBY's Net-margin (%) is ranked higher than
94% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. RHHBY: 23.15 )
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.54   Max: 30.16
Current: 23.15

-13.54
30.16
ROE (%) 56.81
RHHBY's ROE (%) is ranked higher than
98% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. RHHBY: 56.81 )
RHHBY' s 10-Year ROE (%) Range
Min: -16.17   Max: 82.24
Current: 56.81

-16.17
82.24
ROA (%) 17.58
RHHBY's ROA (%) is ranked higher than
96% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. RHHBY: 17.58 )
RHHBY' s 10-Year ROA (%) Range
Min: -5.78   Max: 17.58
Current: 17.58

-5.78
17.58
ROC (Joel Greenblatt) (%) 79.20
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. RHHBY: 79.20 )
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.31   Max: 84.52
Current: 79.2

6.31
84.52
Revenue Growth (%) -0.70
RHHBY's Revenue Growth (%) is ranked higher than
77% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. RHHBY: -0.70 )
RHHBY' s 10-Year Revenue Growth (%) Range
Min: -2.3   Max: 391.7
Current: -0.7

-2.3
391.7
EBITDA Growth (%) 5.10
RHHBY's EBITDA Growth (%) is ranked higher than
82% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. RHHBY: 5.10 )
RHHBY' s 10-Year EBITDA Growth (%) Range
Min: -5.1   Max: 332.7
Current: 5.1

-5.1
332.7
EPS Growth (%) 8.60
RHHBY's EPS Growth (%) is ranked higher than
84% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. RHHBY: 8.60 )
RHHBY' s 10-Year EPS Growth (%) Range
Min: -3.8   Max: 341.1
Current: 8.6

-3.8
341.1
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

RHHBY Guru Trades in Q4 2013

Bill Frels 1,013,940 sh (+66.16%)
Ken Fisher 906,056 sh (-0.26%)
» More
Q1 2014

RHHBY Guru Trades in Q1 2014

Ken Fisher 1,803,070 sh (+99%)
Bill Frels 2,138,396 sh (+5.45%)
» More
Q2 2014

RHHBY Guru Trades in Q2 2014

Bill Frels 2,184,810 sh (+2.17%)
Ken Fisher 1,813,443 sh (-49.71%)
» More
Q3 2014

RHHBY Guru Trades in Q3 2014

Bill Frels 2,391,096 sh (+9.44%)
Ken Fisher 1,891,406 sh (+4.3%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-06-30 Reduce -49.71%0.07%$35.42 - $38.07 $ 37.211%1813443
Ken Fisher 2014-03-31 Add 99%0.07%$18.14 - $38.17 $ 37.2125%1803070
Tweedy Browne 2013-06-30 Sold Out $28.92 - $32.98 $ 37.2120%0
Ken Fisher 2013-03-31 Add 634.57%0.12%$25.25 - $29.3 $ 37.2134%897861
Tweedy Browne 2012-09-30 Reduce -24.31%0.03%$20.95 - $24.07 $ 37.2166%62164
Vanguard Health Care Fund 2012-06-30 Add 543.36%2.96%$19.47 - $23.14 $ 37.2176%4273977
Ken Fisher 2012-06-30 Reduce -24.26%0.01%$19.47 - $23.14 $ 37.2176%154713
Ken Fisher 2012-03-31 Reduce -98.02%1.27%$21.55 - $22.17 $ 37.2186%204276
Tweedy Browne 2012-03-31 Reduce -22.19%0.04%$21.55 - $22.17 $ 37.2186%82130
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.70
RHHBY's P/E(ttm) is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 21.70 )
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.05   Max: 53.68
Current: 21.7

13.05
53.68
P/B 11.30
RHHBY's P/B is ranked higher than
63% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. RHHBY: 11.30 )
RHHBY' s 10-Year P/B Range
Min: 2.64   Max: 17.39
Current: 11.3

2.64
17.39
P/S 5.40
RHHBY's P/S is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. RHHBY: 5.40 )
RHHBY' s 10-Year P/S Range
Min: 2.38   Max: 6.09
Current: 5.4

2.38
6.09
PFCF 18.80
RHHBY's PFCF is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 18.80 )
RHHBY' s 10-Year PFCF Range
Min: 8.6   Max: 39.65
Current: 18.8

8.6
39.65
EV-to-EBIT 15.05
RHHBY's EV-to-EBIT is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 15.05 )
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 29.9
Current: 15.05

7.9
29.9
PEG 4.41
RHHBY's PEG is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 4.41 )
RHHBY' s 10-Year PEG Range
Min: 0.23   Max: 4.52
Current: 4.41

0.23
4.52
Shiller P/E 25.00
RHHBY's Shiller P/E is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 25.00 )
RHHBY' s 10-Year Shiller P/E Range
Min: 13.46   Max: 110.34
Current: 25

13.46
110.34
Current Ratio 1.85
RHHBY's Current Ratio is ranked higher than
58% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. RHHBY: 1.85 )
RHHBY' s 10-Year Current Ratio Range
Min: 1.55   Max: 3.75
Current: 1.85

1.55
3.75
Quick Ratio 1.48
RHHBY's Quick Ratio is ranked higher than
57% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. RHHBY: 1.48 )
RHHBY' s 10-Year Quick Ratio Range
Min: 1.28   Max: 3.22
Current: 1.48

1.28
3.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.00
RHHBY's Dividend Yield is ranked higher than
88% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. RHHBY: 3.00 )
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74   Max: 4.55
Current: 3

0.74
4.55
Dividend Payout 0.63
RHHBY's Dividend Payout is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 0.63 )
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.59
Current: 0.63

0.21
0.59
Dividend growth (3y) -7.30
RHHBY's Dividend growth (3y) is ranked higher than
73% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. RHHBY: -7.30 )
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: -7.3

0
27.3
Yield on cost (5-Year) 2.46
RHHBY's Yield on cost (5-Year) is ranked higher than
77% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. RHHBY: 2.46 )
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 0.61   Max: 3.73
Current: 2.46

0.61
3.73
Share Buyback Rate -0.20
RHHBY's Share Buyback Rate is ranked higher than
94% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. RHHBY: -0.20 )
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 23.59
RHHBY's Price/Tangible Book is ranked higher than
64% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. RHHBY: 23.59 )
RHHBY' s 10-Year Price/Tangible Book Range
Min: 5.17   Max: 95.2
Current: 23.59

5.17
95.2
Price/DCF (Projected) 1.89
RHHBY's Price/DCF (Projected) is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 1.89 )
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.16   Max: 3.61
Current: 1.89

1.16
3.61
Price/Median PS Value 1.28
RHHBY's Price/Median PS Value is ranked higher than
81% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. RHHBY: 1.28 )
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 1.32
Current: 1.28

0.64
1.32
Price/Graham Number 4.69
RHHBY's Price/Graham Number is ranked higher than
91% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 4.69 )
RHHBY' s 10-Year Price/Graham Number Range
Min: 1.78   Max: 7.97
Current: 4.69

1.78
7.97
Earnings Yield (Greenblatt) 6.60
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. RHHBY: 6.60 )
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.3   Max: 12.7
Current: 6.6

3.3
12.7
Forward Rate of Return (Yacktman) 9.13
RHHBY's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. RHHBY: 9.13 )
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 170.5
Current: 9.13

2.2
170.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.UK, 0QOK.UK, ROG N.Mexico
Roche Holding AG Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. It has more than 60 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Diagnostics division includes five business areas: Applied Science, Molecular Diagnostics, Professional Diagnostics, Tissue Diagnosis and Diabetes Care.
» More Articles for RHHBY.PK

Headlines

Articles On GuruFocus.com
The Top 5 European Stocks Held During Q3 Nov 25 2014 
Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
Widely Held Guru Stocks Trading In Europe Sep 22 2014 
Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
Signature Select Canadian Fund's Top Holdings Jul 02 2014 
The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
Most Popular International Stocks of Investment Gurus Mar 05 2014 
John Rogers' Ariel Fund Comments on Roche Feb 28 2014 
Ariel International Fund & Ariel Global Fund - Healthy Ideas Feb 28 2014 


More From Other Websites
Immunomedics' Veltuzumab Receives Orphan Drug Status Nov 24 2014
AstraZeneca Targets More than $45B in Revenues in 2023 Nov 19 2014
Inovio-Roche End Deal for Development of Cancer Therapy Nov 18 2014
Celldex Therapeutics Surges on Positive Rindopepimut Data Nov 18 2014
Roche's (RHHBY) Avastin Label Expansion Approved by FDA Nov 18 2014
Puma Biotechnology Falls on Disappointing Neratinib Data Nov 17 2014
Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients Nov 14 2014
FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy to Treat Women with... Nov 14 2014
Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer Nov 13 2014
Roche Teams Up with LabCentral to Support Biotech Startups Nov 12 2014
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data Nov 12 2014
PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y Nov 11 2014
Dr. Reddy's Laboratories: The Bridge to 2016 Nov 10 2014
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? Nov 07 2014
FDA revokes Ranbaxy’s right to generic versions of Nexium, Valcyte Nov 06 2014
[$$] FDA Says Ranbaxy Can't Make Generic Versions of Nexium, Valcyte Nov 06 2014
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter Nov 04 2014
Will Exelixis (EXEL) Disappoint This Earnings Season? Nov 03 2014
Will Teva (TEVA) Beat Q3 Earnings on Strong Generic Sales? Oct 29 2014
Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer... Oct 28 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK